Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Целесообразность применения Нейромультивита в комплексной патогенетической терапии диабетической нейропатии
Целесообразность применения Нейромультивита в комплексной патогенетической терапии диабетической нейропатии
Е.В.Бирюкова, Е.В.Романова. Целесообразность
применения Нейромультивита в комплексной патогенетической терапии диабетической
нейропатии. Справочник поликлинического врача. 2014; 10: 30–32.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Said G. Diabetic Neuropathy. A Review Nat Clin Pract Neurol 2007; 3 (6): 331–40.
2. Kempler P. Neuropathies. Pathomechanism, clinical presentation, diagnosis, therapy. Budapest: Springer Scientific Publisher, 2002.
3. Fazan VPS, de Vasconcelos CAC. Valença M.M. Diabetic peripheral neuropathies: a morphometric overview. Int J Morphol 2010; 28 (1): 51–64.
4. Thornalley PJ, Babaei-Jadidi R, Al Ali H et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007; 50: 2164–70.
5. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005; 54: 1615–25.
6. Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. Curr Diabetes Rev 2005; 1: 287–98.
7. Herman WH, Kennedy L for the GOAL A1c study. Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care 2005; 28: 1480–1.
8. Thornalley PJ, Jahan I, Ng R. Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human rede blood cells during huperglycaemia by thiamine in vitro. J Biochem 2001; 129: 543–9.
9. Boulton AJM, Kirsner RS, Vileikyte L. Neuropathic diabetic foot ulcers. New Engl J Med 2004; 351: 48–55.
10. Solomon L.R. Disorders of cobalamin (vitamin B12) metabolism: emerging concept in patophysiology, diagnosis and treatment. Blood Rev 2007; 21: 113–30.
2. Kempler P. Neuropathies. Pathomechanism, clinical presentation, diagnosis, therapy. Budapest: Springer Scientific Publisher, 2002.
3. Fazan VPS, de Vasconcelos CAC. Valença M.M. Diabetic peripheral neuropathies: a morphometric overview. Int J Morphol 2010; 28 (1): 51–64.
4. Thornalley PJ, Babaei-Jadidi R, Al Ali H et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007; 50: 2164–70.
5. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005; 54: 1615–25.
6. Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. Curr Diabetes Rev 2005; 1: 287–98.
7. Herman WH, Kennedy L for the GOAL A1c study. Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care 2005; 28: 1480–1.
8. Thornalley PJ, Jahan I, Ng R. Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human rede blood cells during huperglycaemia by thiamine in vitro. J Biochem 2001; 129: 543–9.
9. Boulton AJM, Kirsner RS, Vileikyte L. Neuropathic diabetic foot ulcers. New Engl J Med 2004; 351: 48–55.
10. Solomon L.R. Disorders of cobalamin (vitamin B12) metabolism: emerging concept in patophysiology, diagnosis and treatment. Blood Rev 2007; 21: 113–30.
Авторы
Е.В.Бирюкова, Е.В.Романова
ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России
ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.